Company intelligence / Profile preview

Ypsilon Therapeutics

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Ypsilon Therapeutics is developing next-generation T-cell receptor mimic (TCRm) bispecific antibodies that can recognize intracellular tumor-derived antigens presented by pMHC, aiming to provide new treatments for difficult-to-treat solid tumors; the current lead candidate is advancing toward drug candidate nomination with CPRIT funding support[1][2][3].

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBispecific monoclonal antibodyAntibody
Industry: Biotech

Partnerships

Alloy Therapeutics82VS (venture studio of Alloy Therapeutics)

Beyond the preview

Go deeper on Ypsilon Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ypsilon Therapeutics.

Explore the full profile